Energy expenditure in myelofibrosis patients treated with a JAK1/2 inhibitor

被引:1
作者
Tremblay, Douglas [1 ]
Dougherty, Mikaela [1 ]
Mascarenhas, John [1 ]
Gallagher, Emily Jane [2 ]
机构
[1] Icahn Sch Med Mt Sinai, Tisch Canc Inst, New York, NY 10029 USA
[2] Icahn Sch Med Mt Sinai, Dept Med, Div Endocrinol Diabet & Bone Dis, New York, NY USA
来源
FRONTIERS IN ENDOCRINOLOGY | 2023年 / 14卷
关键词
ruxolitinib; energy expenditure; weight gain; intolerance; leptin; RUXOLITINIB; LEPTIN;
D O I
10.3389/fendo.2023.1141029
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Weight gain is a known adverse effect of ruxolitinib, a JAK1/2 inhibitor that is the mainstay of treatment for many patients with myelofibrosis. The mechanisms behind weight increase with ruxolitinib is incompletely understood, although decreased adipose tissue lipolysis and increased appetite due to blocking the effects of leptin in the hypothalamus have been proposed. In order to explore the metabolic changes in ruxolitinib-treated patients with myelofibrosis, we performed a pilot study to assess the feasibility of using a portable indirect calorimeter to quantify energy expenditure before and during ruxolitinib treatment and report the results of two patients. Waist circumference increased during ruxolitinib treatment in both patients. Energy expenditure initially increased followed by a decrease and then increase again, but to levels below baseline. These results suggest that weight gain secondary to ruxolitinib may be related to changes in whole body energy expenditure.
引用
收藏
页数:5
相关论文
共 14 条
  • [1] Myeloproliferative Neoplasm (MPN) Symptom Assessment Form Total Symptom Score: Prospective International Assessment of an Abbreviated Symptom Burden Scoring System Among Patients With MPNs
    Emanuel, Robyn M.
    Dueck, Amylou C.
    Geyer, Holly L.
    Kiladjian, Jean-Jacques
    Slot, Stefanie
    Zweegman, Sonja
    te Boekhorst, Peter A. W.
    Commandeur, Suzan
    Schouten, Harry C.
    Sackmann, Federico
    Kerguelen Fuentes, Ana
    Hernandez-Maraver, Dolores
    Pahl, Heike L.
    Griesshammer, Martin
    Stegelmann, Frank
    Doehner, Konstanze
    Lehmann, Thomas
    Bonatz, Karin
    Reiter, Andreas
    Boyer, Francoise
    Etienne, Gabriel
    Ianotto, Jean-Christophe
    Ranta, Dana
    Roy, Lydia
    Cahn, Jean-Yves
    Harrison, Claire N.
    Radia, Deepti
    Muxi, Pablo
    Maldonado, Norman
    Besses, Carlos
    Cervantes, Francisco
    Johansson, Peter L.
    Barbui, Tiziano
    Barosi, Giovanni
    Vannucchi, Alessandro M.
    Passamonti, Francesco
    Andreasson, Bjorn
    Ferarri, Maria L.
    Rambaldi, Alessandro
    Samuelsson, Jan
    Birgegard, Gunnar
    Tefferi, Ayalew
    Mesa, Ruben A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (33) : 4098 - 4103
  • [2] Direct and indirect effects of leptin on adipocyte metabolism
    Harris, Ruth B. S.
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE, 2014, 1842 (03): : 414 - 423
  • [3] JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis
    Harrison, Claire
    Kiladjian, Jean-Jacques
    Al-Ali, Haifa Kathrin
    Gisslinger, Heinz
    Waltzman, Roger
    Stalbovskaya, Viktoriya
    McQuitty, Mari
    Hunter, Deborah S.
    Levy, Richard
    Knoops, Laurent
    Cervantes, Francisco
    Vannucchi, Alessandro M.
    Barbui, Tiziano
    Barosi, Giovanni
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (09) : 787 - 798
  • [4] Adipocyte-selective reduction of the leptin receptors induced by antisense RNA leads to increased adiposity, dyslipidemia, and insulin resistance
    Huan, JN
    Li, J
    Han, YP
    Chen, K
    Wu, N
    Zhao, AZ
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (46) : 45638 - 45650
  • [5] Ruxolitinib treatment improves muscle mass in patients with myelofibrosis
    Lucijanic, Marko
    Galusic, Davor
    Soric, Ena
    Sedinic, Martina
    Cubela, Marta
    Huzjan Korunic, Renata
    Pejsa, Vlatko
    Kusec, Rajko
    [J]. ANNALS OF HEMATOLOGY, 2021, 100 (04) : 1105 - 1106
  • [6] Biological drivers of clinical phenotype in myelofibrosis
    Mascarenhas, John
    Gleitz, Helene F. E.
    Chifotides, Helen T.
    Harrison, Claire N.
    Verstovsek, Srdan
    Vannucchi, Alessandro Maria
    Rampal, Raajit K.
    Kiladjian, Jean-Jacques
    Vainchenker, William
    Hoffman, Ronald
    Schneider, Rebekka K.
    List, Alan F.
    [J]. LEUKEMIA, 2023, 37 (02) : 255 - 264
  • [7] Effects of Ruxolitinib Treatment on Metabolic and Nutritional Parameters in Patients With Myelofibrosis From COMFORT-I
    Mesa, Ruben A.
    Verstoysek, Srdan
    Gupta, Vikas
    Mascarenhas, John O.
    Atallah, Ehab
    Burn, Timothy
    Sun, William
    Sandor, Victor
    Gotlib, Jason
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2015, 15 (04) : 214 - 221
  • [8] Ruxolitinib can cause weight gain by blocking leptin signaling in the brain via JAK2/STAT3
    Molle, Nicole
    Krichevsky, Spencer
    Kermani, Pouneh
    Silver, Richard T.
    Ritchie, Ellen
    Scandura, Joseph M.
    [J]. BLOOD, 2020, 135 (13) : 1062 - 1066
  • [9] BASAL METABOLIC-RATE IN ADULTS WITH GROWTH-HORMONE DEFICIENCY AND IN PATIENTS WITH ACROMEGALY - RELATIONSHIP WITH LEAN BODY-MASS, PLASMA-INSULIN LEVEL AND LEUKOCYTE SODIUM-PUMP ACTIVITY
    SALOMON, F
    CUNEO, RC
    HESP, R
    MORRIS, JF
    POSTON, L
    SONKSEN, PH
    [J]. CLINICAL SCIENCE, 1992, 83 (03) : 325 - 330
  • [10] Metabolic Effects of JAK1/2 Inhibition in Patients with Myeloproliferative Neoplasms
    Sapre, Manali
    Tremblay, Douglas
    Wilck, Eric
    James, Annie
    Leiter, Amanda
    Coltoff, Alexander
    Koshy, Anita G.
    Kremyanskaya, Marina
    Hoffman, Ronald
    Mascarenhas, John O.
    Gallagher, Emily J.
    [J]. SCIENTIFIC REPORTS, 2019, 9 (1)